The receptor binding properties of H5Ny influenza A viruses have evolved to bind to avian-type mucin-like O-glycans
PLOS Pathogens · 2026
DOI: 10.1371/journal.ppat.1013812 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2026. Verfasst von Julia Weber und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg Utrecht, Utrecht…. Hauptthemen laut MEDLINE: Polysaccharides, Hemagglutinin Glycoproteins, Influenza Virus, Receptors, Virus, Influenza A virus. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIGMS NIH HHS, NCRR NIH HHS.
Abstract (Originalsprache)
Highly pathogenic H5Ny influenza A viruses are causing unprecedented, season-independent outbreaks across avian and mammalian species, including dairy cattle, a novel reservoir. The sialoside-binding properties of influenza A hemagglutinin (HA) are strongly related to its ability to infect and transmit between hosts. Mucin-like O-glycans, omnipresent in respiratory tracts, have been understudied as viral receptors due to their complexity. To address this, we synthesized 25 O-linked glycans with diverse sialosides, including modifications by fucosides and sulfates. Our findings reveal that H5Ny 2.3.4.4b viruses bind core 3 sialyl-Lewis x and Sia-Gal-β3GalNAc, O-linked glycans not recognized by classical H5 or other avian viruses. By determining crystal structures, we resolved the structural features of four glycans in an H5 hemagglutinin (HA) from a 2016 2.3.4.4b virus. While these viruses do not bind human-type receptors, their broad receptor specificity enhances binding to human tracheal tissues, suggesting that O-glycan recognition could contribute to the continues spillover of this clade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg Utrecht, Utrecht, The Netherlands.
- Institute of Applied Synthetic Chemistry, Vienna University of Technology, Vienna, Austria.
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.
- Department of Medical Microbiology & Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
- Department of Viroscience, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California, United States of America.
ORCID-Profile: Robert P de Vries
Förderung
- NIAID NIH HHS
- NIGMS NIH HHS
- NCRR NIH HHS
- ICRAD
- NWO
- Austrian Science Fund
- NIH
Zitieren
APA
Weber, J., Ponse, N. L. D., Zhu, X., Ríos Carrasco, M., Han, A. X., Funk, M., Lin, T. H., Gabarroca García, A., Spruit, C. M., Zhang, D., Yu, W., Wilson, I. A., Richard, M., Boons, G. J., & de Vries, R. P. (2026). The receptor binding properties of H5Ny influenza A viruses have evolved to bind to avian-type mucin-like O-glycans. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1013812
Vancouver
Weber J, Ponse NLD, Zhu X, Ríos Carrasco M, Han AX, Funk M, et al. The receptor binding properties of H5Ny influenza A viruses have evolved to bind to avian-type mucin-like O-glycans. PLOS Pathogens. 2026. doi:10.1371/journal.ppat.1013812
BibTeX
@article{Weber2026,
author = {Weber, Julia and Ponse, Niels L D and Zhu, Xueyong and Ríos Carrasco, María and Han, Alvin X and Funk, Mathis and Lin, Ting-Hui and Gabarroca García, Alba and Spruit, Cindy M and Zhang, Ding and Yu, Wenli and Wilson, Ian A and Richard, Mathilde and Boons, Geert-Jan and de Vries, Robert P},
title = {The receptor binding properties of H5Ny influenza A viruses have evolved to bind to avian-type mucin-like O-glycans},
journal = {PLOS Pathogens},
year = {2026},
doi = {10.1371/journal.ppat.1013812}
}
EUVIMED